The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| STTK | +52.38% | -92.57% | -40.51% | -90% |
| S&P | +19.89% | +109.18% | +15.89% | +97% |
Shattuck Labs, Inc. engages in the research and development of dual-sided fusion proteins used for medical treatment of cancer and autoimmune disease. It primarily focuses on Agonist Redirected Checkpoint (ARC) and Gamma Delta T Cell Engagers (GADLEN) platforms. It develops a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and autoimmune diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.93M | -243.6% |
| Gross Margin | 68.20% | 0.0% |
| Market Cap | $37.93M | -79.3% |
| Market Cap / Employee | $0.86M | 0.0% |
| Employees | 44 | -41.3% |
| Net Income | -$12.46M | 42.2% |
| EBITDA | -$12.10M | 45.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $50.47M | -16.8% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.02M | -32.2% |
| Short Term Debt | $0.96M | 12.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -63.75% | -3.7% |
| Return On Invested Capital | -47.13% | 14.7% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$17.37M | 10.6% |
| Operating Free Cash Flow | -$10.43M | 4.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.51 | 0.60 | 0.57 | 0.56 | -60.59% |
| Price to Sales | 27.57 | 10.75 | 10.51 | 13.47 | -71.66% |
| Price to Tangible Book Value | 1.51 | 0.60 | 0.57 | 0.56 | -60.59% |
| Enterprise Value to EBITDA | -5.36 | 0.43 | 0.69 | 0.59 | -113.67% |
| Return on Equity | -71.1% | -67.2% | -71.9% | -73.4% | 7.17% |
| Total Debt | $3.62M | $3.41M | $3.19M | $2.97M | -22.18% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
